| ￥1200 | |
| A05404 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to Putative lipid scramblase CLPTM1 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human Putative lipid scramblase CLPTM1 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||||||
|
|||||||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
| Target Background | Involved in GABAergic but not glutamatergic transmission. Binds and traps GABAA receptors in the endoplasmic reticulum (ER). Modulates postsynaptic GABAergic transmission, and therefore inhibitory neurotransmission, by reducing the plasma membrane expression of these receptors. Altered GABAergic signaling is one among many causes of cleft palate. |
| Synonyms | HS9; N14; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
